Alexion Pharmaceuticals Statistics Share Statistics Alexion Pharmaceuticals has 0
shares outstanding. The number of shares has increased by null%
in one year.
Shares Outstanding n/a Shares Change (YoY) n/a Shares Change (QoQ) n/a Owned by Institutions (%) n/a Shares Floating n/a Failed to Deliver (FTD) Shares n/a FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 3.09M, so 0% of the outstanding
shares have been sold short.
Short Interest 3.09M Short % of Shares Out n/a Short % of Float n/a Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is 56.73 and the forward
PE ratio is null.
Alexion Pharmaceuticals's PEG ratio is
-0.76.
PE Ratio 56.73 Forward PE n/a PS Ratio 5.64 Forward PS n/a PB Ratio 2.94 P/FCF Ratio 11.82 PEG Ratio -0.76
Financial Ratio History Enterprise Valuation Alexion Pharmaceuticals has an Enterprise Value (EV) of 33.83B.
EV / Sales 5.57 EV / EBITDA 33.73 EV / EBIT 11.27 EV / FCF 11.68
Financial Position The company has a current ratio of 3.59,
with a Debt / Equity ratio of 0.22.
Current Ratio 3.59 Quick Ratio 3.11 Debt / Equity 0.22 Debt / EBITDA 2.55 Debt / FCF 0.88 Interest Coverage 27.32
Financial Efficiency Return on Equity is 5.18% and Return on Invested Capital is 18.25%.
Return on Equity 5.18% Return on Assets 3.33% Return on Invested Capital 18.25% Revenue Per Employee $1.58M Profits Per Employee $157.26K Employee Count 3,837 Asset Turnover 0.34 Inventory Turnover 0.71
Taxes Income Tax -34.4M Effective Tax Rate -6.05%
Stock Price Statistics The stock price has increased by 0% in the
last 52 weeks. The beta is 1.26, so Alexion Pharmaceuticals's
price volatility has been higher than the market average.
Beta 1.26 52-Week Price Change n/a 50-Day Moving Average n/a 200-Day Moving Average n/a Relative Strength Index (RSI) n/a Average Volume (20 Days) 4,222,993
Income Statement In the last 12 months, Alexion Pharmaceuticals had revenue of 6.07B
and earned 603.4M
in profits. Earnings per share was 2.75.
Revenue 6.07B Gross Profit 5.52B Operating Income 2.86B Net Income 603.4M EBITDA 1B EBIT 673.7M Earnings Per Share (EPS) 2.75
Full Income Statement Balance Sheet The company has 2.96B in cash and 2.56B in
debt, giving a net cash position of 402.5M.
Cash & Cash Equivalents 2.96B Total Debt 2.56B Net Cash 402.5M Retained Earnings 5.24B Total Assets n/a Working Capital n/a
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was 3B
and capital expenditures -106.7M, giving a free cash flow of 2.9B.
Operating Cash Flow 3B Capital Expenditures -106.7M Free Cash Flow 2.9B FCF Per Share 13.22
Full Cash Flow Statement Margins Gross margin is 90.88%, with operating and profit margins of 47.12% and 9.94%.
Gross Margin 90.88% Operating Margin 47.12% Pretax Margin 9.37% Profit Margin 9.94% EBITDA Margin 16.53% EBIT Margin 47.12% FCF Margin 47.71%
Dividends & Yields ALXN does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield 1.76% FCF Yield 8.46%
Dividend Details Analyst Forecast Currently there are no analyst rating for ALXN.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value $25 Lynch Upside -86.3% Graham Number 57.4 Graham Upside -68.55%
Stock Splits The last stock split was on May 23, 2011. It was a
forward
split with a ratio of 2:1.
Last Split Date May 23, 2011 Split Type forward Split Ratio 2:1
Scores Altman Z-Score n/a Piotroski F-Score n/a
